Immuno-Oncology Advances in Applied Cellular Analysis - 20

Advances in Applied Cellular Analysis * Continuous Live-Cell Analysis of the Immune-Tumor Axis

throughput (up to 6 x 384 well plates in parallel),
thereby enhancing experimental productivity.

Immune-Cell Killing Assays for Biosimilar
Antibody Potency Determination

Here, we highlight a series of short
test cases to illustrate the application,
utility and value of CLCA to
immuno-oncology research.

More than 20 antibody-based drugs for cancer are
now approved. These include checkpoint inhibitors and new immunotherapies for neuroblastoma
and multiple myeloma. A wide range of novel

antibodies that target the tumor/immune axis are
in clinical development. With further approvals,
there is a growing opportunity to develop biosimilars, the antibody equivalents of generic copy-cat
small molecule drugs. One challenge to achieve
regulatory approval is to demonstrate true biosimilarity, particularly in relevant functional bioassays.
Figure 3. IncuCyte® continuous
live-cell analysis assays for
immuno-oncology research.
(A) Tumor cell proliferation measures via labelfree confluence analysis or nuclear-labeled cell
counts (e.g., NucLight Red). Includes adherent
and suspension cultures, and tumor spheroids.
(B) Invasion and migration assays with
Essen 96-well Scratch Wound system.
(C) Immune cell proliferation and clustering
via label-free confluence analysis.
(D) Directional chemotaxis measurements
including trans-endothelial migration via
IncuCyte ClearView 96-well assay plates.
(E) Immune-cell killing assays including ADCC
using apoptosis markers (Caspase-3/7 and
Annexin V) and tumor cell counting with
nuclear labels.
(F) Measurements of cellular phagocytosis based
on internalization of pH-sensitive dye-labeled
target cells (IncuCyte pHrodo-cell labeling kit).

| GENengnews.com

http://www.GENengnews.com

Immuno-Oncology Advances in Applied Cellular Analysis

Table of Contents for the Digital Edition of Immuno-Oncology Advances in Applied Cellular Analysis